COMMENTARY

Whole Genome Sequencing as a Genetic Test for Autism Spectrum Disorder: From Bench to Bedside and then Back Again

Michael J. Szego PhD, MHSc1,2,3; Ma’n H. Zawati LLB, LLM4

Abstract

Autism spectrum disorder (ASD) is characterized by repetitive patterns of behaviour and impairments in social interactions and communication abilities. Although ASD is a heterogeneous disorder, it is a highly genetic condition for which genetic testing is routinely performed. Microarray analysis is currently the standard of care genetic test for ASD, however whole genome sequencing offers several key advantages and will likely replace microarrays as a frontline genetic test in the near future. The 2nd Consultation on Translation of Genomic Advances into Health Applications took place in the spring of 2014 to broadly explore the current and potential impacts of genomic advances in supporting personalized and family-centered care for autism and related developmental conditions. In anticipation of WGS becoming a standard of care test, we examine the policy landscape and highlight the lack of consistency among guidelines regarding what genomic information should be returned to patients and their families. We also discuss the need to create the infrastructure to share clinical WGS data with researchers in a systematic and ethically defensible manner.

Key Words: autism spectrum disorder, return of results, whole genome sequencing, database, research ethics

Résumé

Le trouble du spectre de l’autisme (TSA) est caractérisé par des comportements répétitifs et des déficiences dans les aptitudes aux interactions sociales et à la communication. Bien que le TSA soit un trouble hétérogène, c’est une affection hautement génétique pour laquelle un test génétique est régulièrement mené. L’analyse par microréseau est présentement la norme de pratique pour le TSA; cependant, le séquençage du génome entier (SGE) offre plusieurs avantages clés et remplacera probablement les microréseaux comme test génétique de première ligne dans un avenir rapproché. La 2e Consultation sur la conversion des progrès de la génomique en applications de santé a eu lieu au printemps de 2014 afin d’explorer largement les effets actuels et potentiels des progrès de la génomique pour soutenir les soins de l’autisme personnalisés et axés sur la famille, et les troubles du développement connexes. En prévision que le SGE devienne la norme de pratique des tests, nous examinons le paysage normatif et soulignons l’absence de cohérence des lignes directrices à l’égard de l’information génomique qui devrait être retournée aux patients et à leurs familles. Nous discutons également du besoin de créer l’infrastructure pour partager les données cliniques du SGE avec les chercheurs de manière systématique et éthiquement défendable.

Mots clés: trouble du spectre de l’autisme, retour des résultats, séquençage du génome entier, base de données, éthique de la recherche

1Centre for Clinical Ethics, St. Joseph’s Health Centre, Toronto, Ontario
2The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Ontario
3Department of Family and Community Medicine, The Dalla Lana School of Public Health, and The Joint Centre for Bioethics, University of Toronto, Toronto, Ontario
4Centre of Genomics and Policy, McGill University, Montreal, Quebec

Corresponding E-Mail: michael.szego@utoronto.ca

Submitted: May 6, 2015; Accepted: March 26, 2016
Background

Autism spectrum disorder (ASD) is characterized by repetitive patterns of behaviour and impairments in social interactions and communication abilities (Anagnostou et al., 2014). Individuals with ASD can present with a wide variety of features, with symptoms ranging from mild to severe (Carter & Scherer, 2013; Scherer & Dawson, 2011). ASD affects approximately 1% of the population and the most recent surveillance data suggest the prevalence is one in 68 among children (Anagnostou et al., 2014; Developmental Disabilities Monitoring Network, 2014). Currently, there are no pharmaceutical agents available to treat the core symptoms of ASD, although there are several promising experimental therapeutics being tested (Anagnostou et al., 2014).

ASD is diagnosed clinically following an extensive assessment (Anagnostou et al., 2014). The diagnostic workup usually includes a detailed medical history, a systematic interactive assessment, an evaluation of other co-morbidities, and genomic testing (Anagnostou et al., 2014). Genomic testing is included in the diagnostic workup since ASD is a highly genetic condition with many known genetic risk factors (Anagnostou et al., 2014; Carter & Scherer, 2013). While no single laboratory test is sufficient for the diagnosis of ASD, identification of genetic risk factors can influence patient management, availability of services, and accuracy of recurrence risk estimates (Carter & Scherer, 2013; Shen et al., 2010).

Genome-wide testing is a part of the standard diagnostic assessment for patients with ASD (Anagnostou et al., 2014; Miller et al., 2010). The discovery that copy number variants — large regions of DNA (>1kb) that can differ in copy number between an individual and a reference genome (Redon et al., 2006) — are more common in patients with ASD has been the driver for this molecular diagnostic approach (Devlin & Scherer, 2012). Historically, cytogenetic analysis was performed to directly visualize chromosomes for any rearrangements, including gains and losses (Miller et al., 2010). Chromosomal microarray technology has replaced cytogenetic analysis as a molecular diagnostic tool for ASD (Miller et al., 2010). Chromosomal microarrays have greater resolution and can detect copy number variants across the entire genome in a single test. However, a limitation of both cytogenetic analysis and chromosomal microarrays is the inability to detect single nucleotide changes.

Single nucleotide changes are more common in single gene disorders, which account for 10% of patients with ASD (Devlin & Scherer, 2012). With the development of next generation sequencing, it is now cost effective to sequence individual genomes (Wetterstrand, 2014). Two common applications of next generation sequencing are whole genome sequencing (WGS), which involves elucidating the complete genomic sequence of an individual, and whole exome sequencing (WES), which involves elucidating the protein coding regions of the genome (about 2-3% of the entire genome). WGS will likely be used for the molecular diagnosis of ASD in the near future since it can detect both copy number variants and single nucleotide changes across the entire genome in a single test (Tammimies et al., 2015; Jiang et al., 2014).

The 2nd Consultation on Translation of Genomic Advances into Health Applications took place in the spring of 2014 to broadly explore the current and potential impacts of genomic advances in supporting personalized and family-centered care for autism and related developmental conditions. The consultation event was attended by 50 basic, clinical, and social scientists, health practitioners, ethicists, jurists, economists and community stakeholders from the UK and Canada. The purpose of this commentary is to discuss some ethical issues associated with WGS relevant to ASD that were presented as part of the panel discussion on ethics, public policy and health economics. Although many ethical issues have been discussed in the context of WGS (Presidential Commission for the Study of Bioethical Issues, 2012; Tabor, Berkman, Hull, & Bamshad, 2011; Wolf, 2013), for the purposes of this commentary we will focus on the return of results and how using WGS in a clinical context- provided the right infrastructure is in place- could accelerate the pace of ASD research advances.

ASD genomics: from the bench to the clinic

Genomic studies have revealed several features of ASD. First, rare genomic variants, which are present in less than 1% of the general population, account for a large proportion of genetic risk factors associated with ASD (Levy et al., 2011; Marshall et al., 2008; Neale et al., 2012; Sanders et al., 2012). Examples of rare variants that have been associated with ASD risk include single nucleotide variants (SNVs), chromosomal abnormalities and an abnormal number of repeats of specific DNA regions called copy number variants (Devlin & Scherer, 2012). Secondly, both inherited and de novo mutations have been implicated in ASD with de novo mutations present in 10-15% of ASD cases (Devlin & Scherer, 2012). While inherited mutations are transmitted from parents to their children, de novo mutations represent genetic changes that occur for the first time in the affected individual as a result of a mutation in the germ cell of one of their parents or in the early embryo itself.

Third, there are likely hundreds of genes associated with ASD-risk (Devlin & Scherer, 2012; Pinto et al., 2014).
Some ASD-risk variants are associated with single gene disorders in which patients often exhibit ASD as part of their phenotype. For example, genetic disorders such as Fragile X, tuberous sclerosis, Rett syndrome, and neurofibromatosis are present in 10% of patients with ASD (Devlin & Scherer, 2012). Additional high impact single nucleotide variants and copy number variants have been identified and account for an additional 10% of cases (Scherer & Dawson, 2011).

Interestingly, no single locus accounts for more than 1% of ASD cases (State & Sestan, 2012). Underscoring the genetic heterogeneity of ASD is the finding that in approximately 69% of cases when multiple affected siblings are present in a family, they carry different ASD-relevant mutations (Yuen et al., 2015). This situation is in stark contrast to monogenic disorders when affected siblings would likely have inherited the same mutation. To complicate the picture further, most of the genetic abnormalities associated with ASD are also associated with highly variable phenotypes (Devlin & Scherer, 2012). One suggested explanation for the phenotypic variability is the key role of genetic interactions between rare variants in some individuals (Risch et al., 1999). Ongoing studies such as the autism sequencing project aim to identify the full cadre of variants associated with ASD (Buxbaum et al., 2012). Such efforts will greatly impact patients since a better understanding of the genetic basis of ASD will improve our ability to molecularly diagnose ASD.

Currently, microarray analysis leads to the identification of an ASD-associated variant in about 12% of cases (Miller et al., 2010). Given the genetic complexity associated with ASD, more sensitive techniques may be needed in cases where clinical microarray analysis does not yield any results. WES has been shown to be an effective approach to identify variants associated with ASD risk (Jiang et al., 2014; Rodriguez-Flores et al., 2014). Recently, the diagnostic yield of chromosomal microarray analysis was shown to be comparable to WES, demonstrating the utility of WES (Tammimies et al., 2015). Non coding regions of DNA, which are not interrogated by WES, have been shown to play a role in some cases of ASD (Turner et al., 2016; Walker & Scherer, 2013). As a result, WGS (which interrogates both coding and non coding regions of the genome) will likely replace clinical microarrays as a frontline genetic test in the near future (Jiang et al., 2014). As such, we will focus the next two sections on some ethical issues raised by WGS in the clinical context.

What WGS results to return: exploring the policy landscape

The translation of ASD research tools into the paediatric clinical setting has prompted discussion surrounding the ethical issues of reporting whole-genome sequencing (WGS) results back to patients and families. Consequently, a series of proposals were put forward by various national and international organisations, but no clear consensus exists on the matter. Before exploring this policy landscape, it is important to note that most of the documents featured in this section are, for the most, not binding in nature, but help shape the legal standard of care. In other words, the laws existing in the jurisdiction in question will frame the application of such ethics norms.

In 2013, the European Society of Human Genetics (ESHG) recommended avoiding unsolicited findings by filtering out known genetic variants with limited or no clinical utility (van El et al., 2013). Respect for patient autonomy was a matter of intense debate following the release of the American College of Medical Geneticists (ACMG) recommendations on the reporting of incidental findings from clinical WGS/WES in 2013 (Burke et al., 2013; Green et al., 2013). Most noticeably, the ACMG proposed feeding back results emanating from the analysis of 56 medically actionable genes associated with 24 inherited conditions when a patient undergoes WGS/WES. Moreover, they adopted a more permissive approach than the ESHG recommendations by determining that resulting incidental variants should be reported regardless of the age of the patient. More recently, the ACMG revised their initial recommendations (Green et al., 2013) through a series of clarifications and updates (ACMG Board of Directors, 2013a; ACMG Board of Directors, 2013b; ACMG Board of Directors, 2015). These revisions eventually led to the inclusion of an opt-out alternative to the routine analysis of an evolving subset of genes (ACMG Board of Directors, 2015). However, the ACMG proposes that the patient’s decision shall apply to the entire set of genes deemed actionable (ACMG Board of Directors, 2015).

In the Canadian context, Zawati et al. presented a Canadian-specific proposal for a policy on the use of WGS and more explicitly for the return of results (Zawati, Parry, Thorogood, et al., 2014). Ultimately, in Canada, it is recommended to communicate to parents all “results revealing a clinically significant condition that is actionable during childhood”, and this, without the option to opt-out (Zawati, Parry, Thorogood, et al., 2014). However, for the communication of adult-onset genetic conditions, it is suggested that this should be withheld “unless disclosure to the parents could prevent serious harm to their health or that of...
family members as determined on a case-by-case basis, and if such disclosure is desired by the parents” (Zawati, Parry, & Knoppers, 2014). It is important to consider the child’s views in the decision-making process depending on age and maturity (Zawati, Parry, & Knoppers, 2014). Subsequently, the Canadian College of Medical Geneticists (CCMG) formed two working groups tasked with emitting a position statement on the clinical application of genome-wide sequencing for monogenic diseases (Zawati, Parry, Thorogood, et al., 2014). The criteria set forth for the communication of incidental findings in children primarily revolves around the assessment of medical-actionability during childhood. Ethical decision-making as presented in the national and international proposals mentioned above evoke the consideration of four guiding principles: integrity, beneficence, non-maleficence and justice (Zawati, Parry, & Knoppers et al., 2014). That said, the child’s best interests will fundamentally guide all current recommendations regarding the return of WGS results in the clinical paediatric setting.

**WGS and ASD: from bedside to bench**

Research and clinical care are typically regarded as separate endeavors. In the discussion above, we explored the policy landscape guiding the return of WGS results to patients. Once WGS becomes an established clinical test, the resulting sequence data could be of great utility to the research community. In particular, access to clinical WGS data sets could accelerate current gene-finding efforts, provide more data on genotype-phenotype relationships and serve as a potential source of longitudinal data. In anticipation of the broad use of WGS in ASD genetic testing, models of data sharing between clinical and research environments should be explored.

Currently, when a clinical microarray is ordered as a genetic test for ASD, the data cannot automatically be used for research. The secondary use of clinical data for research purposes requires research ethics board approval and under most circumstances explicit research subject consent (Canadian Institutes of Health Research et al., 2014). As WGS replaces microarray technology, maintaining the status quo entails putting the onus on individual investigators to apply for access to clinical data. A more standardized approach to research data collection could benefit researchers and patients alike. One such approach involves emulating a database model in which clinical WGS and phenotypic data of patients undergoing testing would be collected and stored for future use in research.

Explicit consent is usually required when prospectively collecting patient data for research purposes (Canadian Institutes of Health Research et al., 2014). At the time of clinical consent for WGS, patients could be asked whether they would agree to allow their clinical information to be included in a research database. This additional research consent would include a discussion of the potential benefits and risks of participating, including privacy risks. Prospective participants would also be assured that they could continue to receive the same standard of clinical care regardless of their decision to participate in research. An assent process would also need to be created for paediatric patients who do not yet have the capacity to consent; however, given that ASD genetic testing usually occurs at a young age, substitute decision makers would normally be consenting. Furthermore, if the database is intended as a long-term project, then a process to re-consent participants when they gain the capacity to do so would need to be established.

Databases require an appropriate governance structure and procedures to obtain data and to share data. Creating a data access committee to scrutinize data access requests is one way to control the flow of information. Data sharing is another consideration and organizations like the Global Alliance for Genomics and Health are working towards standardizing ethics review and data harmonization internationally (Knoppers, 2014). A significant advantage of depositing clinical WGS data for research purposes is that a healthcare professional has already returned clinically relevant data. Researchers will have a more manageable task of creating provisions to return any clinically relevant data identified in the future.

**Conclusion**

ASD is a complex disease for which genomic testing can reveal useful clinical information for patients, families, and healthcare providers. In the near future, WGS will likely replace microarrays as being the standard of care genomic test for ASD. For paediatric patients who have their genome sequenced there is a lack of consistency among guidelines regarding what genomic information should be returned to patients and their families. With the wealth of information generated by WGS, we have an opportunity to improve the health of children by testing for variants associated with actionable childhood disorders in addition to ASD-associated variants. However, before this additional testing occurs consistently, laboratories need guidance so they can build the necessary bioinformatics pipelines. In anticipation of WGS becoming a standard of care genomic test, we have the opportunity to creating new infrastructure to share clinical data with researchers in a systematic and ethically defensible manner. Data sharing could increase the pace of genetic discoveries, which would benefit current and future patients.
Acknowledgements / Conflicts of Interest

MJS is supported by funding from a Genome Canada Large Scale Applied Research Project grant, “Autism Spectrum Disorders: Genomes to Outcomes” (Principal investigators S. Scherer and P. Szatmari). MHZ is supported by the Réseau de génétique appliquée du Québec (RMGA). The authors would like to thank Me Erika Kleiderman, Academic Associate at the Centre of Genomics and Policy, for her assistance. The authors have no financial relationships to disclose.

References


ACMG Board of Directors. (2013b). Points to consider for informed consent for genome/exome sequencing. Genetics in Medicine, 15(9), 748-749. doi: 10.1038/gim.2013.94


Burke, W., Antonmaria, A. H., Bennett, R., Botkin, J., Clayton, E. W., Henderson, G. E.,...Zimmerm, R. (2013). Recommendations for returning genomic incidental findings? We need to talk! Genetics in Medicine, 15(11), 854-859. doi: 10.1038/gim.2013.113


---

**Child and Adolescent Psychiatrist**

**Background:**

This is an exceptional opportunity for a dynamic and motivated Child and Adolescent Psychiatrist to take a leadership role in developing a new Child and Youth Mental Health Program for the region.

Located just over an hour north of Toronto, the Child and Youth Mental Health Program (CYMH) is a strategic priority for this Regional Health Centre serving a catchment area of about 450,000 people.

The Regional CYMH Program will provide a comprehensive range of interrelated services including acute mental health inpatient care (new 8 bed unit), acute outpatient services, acute crisis services, a day hospital program and coordination with a wide range of service providers across the region. In collaboration with the adult mental health service the CYMH Program will work to effectively manage transition from young adult to adult services. The Child and Youth Mental Health Program supports a culture of innovation, family centered service and evidence based interventions, and will be moving into redeveloped space in late 2016.

**Position Overview:**

Working in partnership with health and community services, School Boards and the designated regional Lead Agencies (2) to provide care across the continuum, the Psychiatrist will provide psychiatric services including evidence-based assessment, treatment and consultation in line with the mission and values of the Regional Health Centre. As a key member of the Child and Youth Mental Health Program, the Psychiatrist will supervise the assessment and treatment of children with mental health concerns, provide consultation and make treatment decisions as part of the team of clinicians working with children and families involved in the service. Other attributes of the position include:

- Program supported by Clinical Chief, Management Team, Nurses, Social Workers, Occupational Therapists, Recreational Therapists and a Psychologist
- 8 bed inpatient unit in development, interim 4 bed unit in operation
- Full pediatric medical support
- Successful and sought after Family Medicine Teaching Program with teaching opportunity and faculty appointment at the University of Toronto
- Hospital based activity is fully supported with no overhead cost
- Option to establish private community office
- Remuneration:
  - Combination of on-call stipend, sessional fees and OHIP billings provide for exceptional income potential
- No overhead expenses
- Office space and administrative support provided in the hospital

**Qualifications:**

A demonstrated leader with a vision and a collaborative approach to treatment, you are a natural communicator who will act as the primary liaison with key stakeholders. Previous experience developing similar programs preferred.

Suitable candidates should have a minimum of three years of clinical experience as a Child and Adolescent Psychiatrist and hold FRCP(C) designation, or eligible to obtain one, as well as a physician management education program (or are willing to complete).

In accordance with immigration requirements, preference given to Canadian citizens and Permanent Residents.

Interested candidates please contact:

Hedi Cameron,
Regional Manager, CanAm Physician Recruiting Inc.
Office: 647-883-7185
Email: hcameron@canamrecruiting.com
www.canamrecruiting.com